Basic Information
Gohibic
Regulatory Information
EMEA/H/C/006123
January 13, 2025
November 14, 2024
February 3, 2025
Company Information
Germany
Winzerlaer Strasse 2 Ammerbach 07745 Jena
InflaRx GmbH
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Gohibic is indicated for the treatment of adult patients with SARS-CoV2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of Standard of Care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygenation (ECMO)).
Overview Summary
Gohibic is a medicine used to treat acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 (the virus that causes COVID-19). ARDS is a condition in which swelling in the lungs causes inflammation and fluid to build up in the air sacs, causing severe difficulty breathing. Gohibic is used in adults who are being treated with corticosteroid (medicines to reduce inflammation) and mechanical ventilation (breathing assisted by a machine) with or without extracorporeal membrane oxygenation (ECMO, life support that can help a person whose lungs and heart aren't working properly). Gohibic contains the active substance vilobelimab.